JP2019515688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515688A5 JP2019515688A5 JP2019506546A JP2019506546A JP2019515688A5 JP 2019515688 A5 JP2019515688 A5 JP 2019515688A5 JP 2019506546 A JP2019506546 A JP 2019506546A JP 2019506546 A JP2019506546 A JP 2019506546A JP 2019515688 A5 JP2019515688 A5 JP 2019515688A5
- Authority
- JP
- Japan
- Prior art keywords
- aon
- ush2a
- mrna
- skipping
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1607141.7 | 2016-04-25 | ||
| GB201607141 | 2016-04-25 | ||
| PCT/EP2017/059830 WO2017186739A1 (en) | 2016-04-25 | 2017-04-25 | Oligonucleotides to treat eye disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515688A JP2019515688A (ja) | 2019-06-13 |
| JP2019515688A5 true JP2019515688A5 (cg-RX-API-DMAC10.html) | 2020-06-11 |
| JP7043082B2 JP7043082B2 (ja) | 2022-03-29 |
Family
ID=58672573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506546A Expired - Fee Related JP7043082B2 (ja) | 2016-04-25 | 2017-04-25 | 眼疾患を処置するオリゴヌクレオチド |
Country Status (15)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| MX2018013003A (es) | 2016-04-25 | 2019-01-28 | Proqr Therapeutics Ii Bv | Oligonucleotidos para tratar una enfermedad ocular. |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| GB201706009D0 (en) | 2017-04-13 | 2017-05-31 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of stargardt disease |
| CA3084633A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| AU2018393050A1 (en) | 2017-12-21 | 2020-06-18 | Bayer Healthcare Llc | Materials and methods for treatment of Usher Syndrome Type 2A |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3918067A1 (en) | 2019-01-28 | 2021-12-08 | ProQR Therapeutics II B.V. | Rna-editing oligonucleotides for the treatment of usher syndrome |
| US20220145305A1 (en) * | 2019-02-12 | 2022-05-12 | Universita' Degli Studi Di Trento | CAS12a GUIDE RNA MOLECULES AND USES THEREOF |
| US20220177894A1 (en) | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
| CA3136735A1 (en) | 2019-04-15 | 2020-10-22 | Edigene Inc. | Methods and compositions for editing rnas |
| US20220213478A1 (en) | 2019-04-18 | 2022-07-07 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of usher syndrome |
| WO2020254249A1 (en) | 2019-06-21 | 2020-12-24 | Proqr Therapeutics Ii B.V. | Delivery of nucleic acids for the treatment of auditory disorders |
| AU2020313143B2 (en) | 2019-07-12 | 2024-04-04 | Peking University | Targeted RNA editing by leveraging endogenous adar using engineered RNAs |
| CA3143071A1 (en) | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
| US20220290154A1 (en) * | 2019-08-08 | 2022-09-15 | Stichting Radboud Universitair Medisch Centrum | Antisense oligonucleotides rescue aberrant splicing of ABCA4 |
| US20230039928A1 (en) | 2019-12-23 | 2023-02-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease |
| AU2020418026A1 (en) * | 2019-12-30 | 2022-08-18 | Edigene Therapeutics (Beijing) Inc. | Method for treating usher syndrome and composition thereof |
| CN113122577A (zh) * | 2019-12-30 | 2021-07-16 | 博雅辑因（北京）生物科技有限公司 | 一种治疗Usher综合征的方法和其组合物 |
| WO2021175904A1 (en) | 2020-03-04 | 2021-09-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of usher syndrome |
| US20240141340A1 (en) | 2021-03-05 | 2024-05-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
| TR2022001648A2 (tr) * | 2022-02-09 | 2022-02-21 | T C Ueskuedar Ueniversitesi | Ush2a kaynaklı retinitis pigmentosa hastalığının genetik tedavisi için ekzon 13 atlama işlevi gören kseno nükleik asit antisens-oligonükleotit (xna-aso) dizileri. |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4599061A1 (en) * | 2022-10-06 | 2025-08-13 | Stichting Radboud universitair medisch centrum | Antisense oligonucleotides for treatment of usher 2a. exon 68 |
| EP4599060A1 (en) * | 2022-10-06 | 2025-08-13 | Stichting Radboud universitair medisch centrum | Antisense oligonucleotides for treatment of usher 2a. exons 30-31 |
| EP4603585A4 (en) * | 2022-10-11 | 2026-06-24 | Guangzhou Reforgene Medicine Co Ltd | RNASN NUCLEIC ACID MOLECULE AND ITS APPLICATION |
| AU2023382528A1 (en) * | 2022-11-15 | 2025-05-15 | Stichting Radboud Universitair Medisch Centrum | Antisense oligonucleotides for treatment of usher 2a. exons 39-40 |
| CN121729244A (zh) * | 2023-07-04 | 2026-03-24 | 广州瑞风生物科技股份有限公司 | 靶向USH2A pre-mRNA假外显子PE40的snRNA及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503713B1 (en) | 1999-10-04 | 2003-01-07 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying RNA binding compounds |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| US20100196889A1 (en) | 2006-11-13 | 2010-08-05 | Bankaitis-Davis Danute M | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer |
| US8093000B2 (en) | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
| US20110070582A1 (en) | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| EP2425814B1 (en) | 2010-09-03 | 2013-06-19 | Novagali Pharma S.A. | A water-in-oil type emulsion for treating a disease of the eye |
| US10131910B2 (en) * | 2014-07-10 | 2018-11-20 | Stichting Katholieke Universiteit | Antisense oligonucleotides for the treatment of Usher syndrome type 2 |
| US9927034B2 (en) | 2015-08-25 | 2018-03-27 | Mueller International, Llc | Valve seat stiffener |
| AU2016335032B2 (en) | 2015-10-05 | 2022-04-14 | Proqr Therapeutics Ii B.V. | Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion |
| MX2018013003A (es) | 2016-04-25 | 2019-01-28 | Proqr Therapeutics Ii Bv | Oligonucleotidos para tratar una enfermedad ocular. |
-
2017
- 2017-04-25 MX MX2018013003A patent/MX2018013003A/es unknown
- 2017-04-25 JP JP2019506546A patent/JP7043082B2/ja not_active Expired - Fee Related
- 2017-04-25 EA EA201892431A patent/EA201892431A1/ru unknown
- 2017-04-25 CA CA3021899A patent/CA3021899A1/en active Pending
- 2017-04-25 DK DK17721984.7T patent/DK3448999T3/da active
- 2017-04-25 WO PCT/EP2017/059830 patent/WO2017186739A1/en not_active Ceased
- 2017-04-25 ES ES17721984T patent/ES2801823T3/es active Active
- 2017-04-25 KR KR1020187031243A patent/KR102368920B1/ko not_active Expired - Fee Related
- 2017-04-25 PL PL17721984T patent/PL3448999T3/pl unknown
- 2017-04-25 EP EP17721984.7A patent/EP3448999B1/en active Active
- 2017-04-25 AU AU2017257292A patent/AU2017257292A1/en not_active Abandoned
- 2017-04-25 US US16/096,038 patent/US10617707B2/en active Active
- 2017-04-25 CN CN201780025611.3A patent/CN109072239A/zh active Pending
-
2018
- 2018-10-05 ZA ZA2018/06628A patent/ZA201806628B/en unknown
- 2018-10-08 IL IL262199A patent/IL262199B/en unknown
-
2020
- 2020-03-06 US US16/811,848 patent/US11123360B2/en not_active Expired - Fee Related
-
2021
- 2021-09-15 US US17/475,795 patent/US20210401871A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7043082B2 (ja) | 眼疾患を処置するオリゴヌクレオチド | |
| Loera‐Valencia et al. | Targeting Alzheimer's disease with gene and cell therapies | |
| KR102450757B1 (ko) | 안 질환 치료용 안티센스 올리고뉴클레오타이드 | |
| JP2021097675A (ja) | 中枢神経系を標的化したａａｖベクター | |
| Machalińska et al. | Long-term neuroprotective effects of NT-4–engineered mesenchymal stem cells injected intravitreally in a mouse model of acute retinal injury | |
| RU2723101C2 (ru) | Вектор, способ лечения хороидермии, способ селективной экспрессии полинуклеотида | |
| JP2017535266A (ja) | 筋萎縮性側索硬化症（ａｌｓ）を治療する組成物および方法 | |
| CN101072866A (zh) | 通过施用rna改变细胞性质的方法 | |
| JP2022552408A (ja) | 神経障害の治療のための細胞外小胞系薬剤及び方法 | |
| JP2013040204A (ja) | コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療 | |
| JP2024042096A (ja) | 神経幹細胞組成物および神経変性障害を処置するための方法 | |
| Melone et al. | Huntington's disease: new frontiers for molecular and cell therapy | |
| CN117242173A (zh) | 产生成熟角膜内皮细胞的方法 | |
| US20240392261A1 (en) | Factor for direct conversion of motor nerve cells | |
| US20220088052A1 (en) | Tfap2 inhibition for treating cardiac disease involving fibro-fatty replacement | |
| CN117500530A (zh) | α-突触核蛋白抑制用组合物及聚集抑制方法 | |
| JP2023513188A (ja) | 遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤 | |
| CN114045288A (zh) | 靶向敲降SIRT2基因的shRNA及烟酰胺腺嘌呤二核苷酸的前体在制备治疗神经退行性疾病的药物中的应用 | |
| WO2022186089A1 (ja) | 神経変性疾患治療のためのポリヌクレオチド、ベクター、細胞、医薬組成物及びスクリーニング方法 | |
| Hu | Survival and Axonal Regeneration of Retinal Ganglion Cells in a Mouse Optic Nerve Crush Model After a Delayed Cell-Based Intravitreal Co-Therapy with Ciliary Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor | |
| JP7765594B2 (ja) | アルファ－シヌクレイン凝集抑制用組成物及び凝集抑制方法 | |
| KR20080025173A (ko) | 양막 세포 및 그의 사용방법 | |
| WO2015097920A1 (ja) | 角膜内皮細胞の細胞治療併用剤 | |
| US20260103704A1 (en) | Antisense oligonucleotides for treatment of USHER 2A. Exon 68 | |
| US20250388899A1 (en) | Rna interference oligonucleotides for inhibiting perineuronal network formation |